Download PDF
Thromb Haemost 1968; 19(03/04): 389-396
DOI: 10.1055/s-0038-1651217
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Properties of 3-(1-Phenyl-Propyl)-4-Oxycoumarin (Marcoumar®) in the Plasma when Tested in Normal Cases and under the Influence of Drugs

K Seiler
1   Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the Department of Medicine (Head: Prof. Dr. F. Koller) of the University, Basel, Switzerland
,
F Duckert
1   Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the Department of Medicine (Head: Prof. Dr. F. Koller) of the University, Basel, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

A fluorimetric method served to determine Marcoumar in blood plasma. The biological half-time of Marcoumar after an administration of 2.2 mg/10 kg is 6½ days. Variations in maintenance dose requirements seem not to be primarly determined by differences in absorption or excretion of the anticoagulant drug. In therapeutical concentrations about 99% of the drug are bound to plasma protein. Marcoumar can be displaced in vitro from plasma protein by different drugs. The anticoagulant effect is not increased in every case in which the anticoagulant is displaced in plasma from its protein binding.

 

  • References

  • 1 Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar [3-(l’-Phenyl-propyl)-4-oxy-cumarin] und seinen Antagonisten Konakion (synthetisches Vitamin K1). Schweiz. med. Wschr. 1953; 83 (20) 471
    PubMedGoogle Scholar
  • 2 Koller F, Jakob H. Über ein neues, hochaktives Antikoagulans mit protrahierter Wirkung (Marcoumar). Schweiz. med. Wschr. 1953; 83 (20) 476
    PubMedGoogle Scholar
  • 3 Deutsch E, Hueber E.F, Mayer E, Wohlrab K. Über die Verwendung eines neuen Antikoagulans. Marcoumar, zur Therapie. Klin. Med. 1954; 2: 49
    PubMedGoogle Scholar
  • 4 Hofstetter J. Bestimmungsmethode für Marcoumar in Blut-Plasma. Personal communication.
    PubMed
  • 5 O’Reilly R.A, Aggeler P.M, Hoag M.S, Leong L. Studies on coumarin anticoagulant drugs: assay of warfarin and its biologic application. Thrombos. Diathes. haemorrh. (Stuttg.) 1962; 5: 82
    PubMedGoogle Scholar
  • 6 Feigl F. Test through conversion into fluorescing alkali salt of o-hydroxycinnamic acid. J. Amer. chem. Soc. 1955; 77: 4162
    CrossrefPubMedGoogle Scholar
  • 7 Dettli L, Spring P. Pharmakokinetik der Chemotherapeutika: Theorie und Praxis. Regensburg. Jb. ärztl. Fortbild. 1966; 14: 17
    PubMedGoogle Scholar
  • 8 Aggeler P. M, O’Reilly R. A. The pharmacological basis of oral anticoagulant therapy. In: Pathogenesis and Treatment of thromboembolic Diseases. Internat. Symposium Basle. ed Koller F, Duckert F, Streuli F, Schattauer F. K. Stuttgart 1965
    Google Scholar
  • 9 Douglas A.S. Anticoagulant therapy. Blackwell Scientific Publications; Oxford: 1962
  • 10 Anton A.H. The relation between the binding of sulfonamides to albumin and their antibacterial efficacy. J. Pharmacol. exp. Ther. 1960; 129: 282
    PubMedGoogle Scholar
  • 11 Anton A.H. A drug-induced change in the distribution and renal excretion of sulfonamides. M. Pharmacol. exp. Therap. 1961; 134: 291
    PubMedGoogle Scholar
  • 12 Newbould B.B, Kilpatrick R. Long-acting sulphonamides and protein-binding. Lancet 1960; I: 887
    PubMedGoogle Scholar
  • 13 Aggeler P.M, O’Reilly R.A, Leong L, Kowitz P.E. Potentiation of anticoagulant effect of Warfarin by phenylbutazone. New Engl. J. Med. 1967; 276: 496
    CrossrefPubMedGoogle Scholar
  • 14 Ghristensen L.K, Hansen J.M, Kristensen M. Sulphaphenazole-induced hypoglycaemic attacks in tolbutamide treated diabetics. Lancet 1963; II: 1298
    PubMedGoogle Scholar
  • 15 Kristensen M, Hansen J.M, Hellerup D. Potentiation of the tolbutamide effect by dicoumarol. Diabetes 1967; 16: 211
    CrossrefPubMedGoogle Scholar
  • 16 Thorp J.M. The influence of plasma proteins on the action of drugs. Absorption and Distribution of Drugs. Binns, T.B., E.S. Livingstone 1964
    PubMed